GlassScriptPhysician profile
Nasreen Wolcott
NPI 1316176431
$3,695.65
in general payments reported to CMS, 2019-2025
21 companies · $1,036 in 2025
The $1,036 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $229 · 2022: $317 · 2023: $859 · 2024: $1,255 · 2025: $1,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,909 · Education: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,908.61 |
| Education | $240.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $805.43 | 2021-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $367.11 | 2023-2025 | |
| Lilly USA, LLC | $340.24 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $326.81 | 2023-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $247.44 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $237.33 | 2024-2025 | Zoryve |
| Amgen INC. | $232.60 | 2023-2025 | Otezla |
| Incyte Corporation | $178.46 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $174.97 | 2023-2024 | Winlevi, Absorica Ld |
| Genzyme Corporation | $170.77 | 2021-2025 | |
| Leo Pharma INC. | $136.77 | 2022-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $111.27 | 2023-2025 | Dupixent |
| Ucb, INC. | $110.57 | 2023-2025 | Bimzelx |
| Dermavant Sciences, INC. | $57.82 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $54.66 | 2022-2024 | Sotyktu |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $29.84 | 2023 | Jublia |
| Biofrontera INC. | $28.37 | 2025 | |
| Kyowa Kirin, INC. | $25.06 | 2022 | |
| Genentech USA, INC. | $23.85 | 2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $20.73 | 2022 | |
| Galderma Laboratories, L.P. | $15.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nasreen Wolcott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.